Aligos Therapeutics Announces $105 Million Private Placement Financing
Proceeds expected to fund the start of the ALG-000184 Phase 2 clinical study Funding expected to extend cash runway into...
Day: February 12, 2025
Standard BioTools Schedules Fourth Quarter and Full Year 2024 Earnings Conference Call on February 26, 2025
SOUTH SAN FRANCISCO, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will...
OKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod
LONDON and NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing...
BioHarvest Sciences to Present at WeBull Consumer Stocks Webinar on February 18
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - February 12, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (CSE: BHSC) (FSE:...
Sona Nanotech’s Targeted Hyperthermia Therapy To Be Presented at the International 19th Canadian Melanoma Conference
Halifax, Nova Scotia--(Newsfile Corp. - February 12, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is...
Glow Lifetech Provides Commercial Update; Continued Growth Momentum with New Product Launch & National Expansion
Toronto, Ontario--(Newsfile Corp. - February 12, 2025) - Glow Lifetech Corp. (CSE: GLOW) (OTC Pink: GLWLF) (FSE: 9DO) ("Glow" or...
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results
Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients SHIELD II...
New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3
- Data Generated to Date Support Potential for Aclaris’ ATI-2138 to Impact Several Human Inflammatory Diseases - WAYNE, Pa., Feb....
Bioxodes secures new funds to reach early 2025 milestones and pursue Series B financing
Bioxodes raises €2.7 million from existing investors in Series A extensionInterim data from BIRCH intracerebral hemorrhage (ICH) Phase 2a trial...
MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs
TG Therapeutics to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support the development and commercialization of azer-cel, its...
Crossject announces the reappointment of Patrick Alexandre and Isabelle Liebschutz as members of new, streamlined Executive Board
Dijon, FRANCE, February 12, 2025 – 0730 (CET) – Crossject (ISIN: FR0011716265; Euronext Growth : ALCJ), a specialty pharma company...
Meet Kayo 1G Live Resin Disposable – The Hemp Doctor’s Newest Heavy Hitter
MOORESVILLE, N.C., Feb. 12, 2025 (GLOBE NEWSWIRE) -- The Hemp Doctor, a trusted name in delivering premium hemp-derived products in...
ÂMÉ Expands to Dubai to Reach Middle Eastern Market
Photo credit: Jen Alsehali DUBAI, United Arab Emirates, Feb. 11, 2025 (GLOBE NEWSWIRE) -- ÂMÉ, a leading luxury skincare brand...
UPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
GOMEKLI™ (mirdametinib) capsules and tablets for oral suspension GOMEKLI™ (mirdametinib) capsules and tablets for oral suspension Saqib Islam, SpringWorks Therapeutics...
Lighthouse Autism Center Announces Expansion of ABA Services in Nebraska
Leading ABA Provider Set to Open Newest Location in Lincoln, NE. Therapy Room at LAC Therapy Room at LAC Therapy...
Microbot Medical Closes $13 Million Registered Direct Offering
BRAINTREE, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced the closing of its previously...
Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025
SAN DIEGO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative...
SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
GOMEKLI™ (mirdametinib) capsules and tablets for oral suspension GOMEKLI™ (mirdametinib) capsules and tablets for oral suspension Saqib Islam, SpringWorks Therapeutics...
Axogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025
ALACHUA, Fla. and TAMPA, Fla., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing...
Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
ROCKVILLE, Md., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and...